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Abstract
Next-generation sequencing has dramatically decreased the cost of gene sequencing, facilitating the simultaneous analysis
of multiple genes at the same time; obtaining a genetic result for an individual patient has become much easier. The article
by Ars and Torra in this issue of the Clinical Kidney Journal provides examples of the ever-increasing ability to understand a
given patient’s disease on the molecular level, so that in some cases not only the causative variants in a disease gene are
identified, but also potential modifiers in other genes. Yet, with increased sequencing, a large number of variants are discov-
ered that are difficult to interpret. These so-called ‘variants of uncertain significance’ raise important questions: when and
how can pathogenicity be clearly attributed? This is of critical importance, as there are potentially serious consequences
attached: decisions about various forms of treatment and even about life and death, such as termination of pregnancy, may
hinge on the answer to these questions. Geneticists, thus, need to use the utmost care in the interpretation of identified var-
iants and clinicians must be aware of this problem. We here discuss the potential of genetics to facilitate personalized treat-
ment, but also the pitfalls and how to deal with them.
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Introduction
Massively parallel sequencing, also called ‘next-generation
sequencing’ (NGS), is revolutionizing the way we perform genetic
testing [1]. Whereas previously, genetic testing typically assessed
one gene at a time, which had to be laboriously amplified in
pieces of 500–800 base pairs, prior to submitting each piece to tra-
ditional (Sanger) sequencing, we now can assess as much genetic
information as desired in one single process. This can range from
a panel of genes specific for the patient’s condition, to all coding
regions of genes (whole exome) to the entire genetic information
(whole genome). Panels are especially helpful in diseases with
genetic heterogeneity, such as Bartter syndrome or steroid-
resistant nephrotic syndrome [2, 3]. Whole exome (WES) or
genome sequencing (WGS) can be especially helpful in cases
where a genetic cause is suspected, but a specific clinical diagno-
sis cannot be established. There are numerous examples for this
also in patients with kidney diseases, including the discovery of
previously unrecognized disease genes and disorders through
WES and WGS [4–7]. The majority of these discoveries have been
achieved with WES, but, increasingly, there are now also reports
of WGS discovering non-coding disease-causing mutations. For
example, our own group recently described a promoter mutation
underlying a previously unrecognized disorder consisting of
hyperinsulinism and polycystic kidney disease [8]. In addition,
WGS can sometimes overcome technical difficulties posed by the
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presence of highly homologous pseudogenes, for instance in the
genetic diagnosis of autosomal dominant polycystic kidney dis-
ease (ADPKD) [9]. These examples highlight the advantages of
such comprehensive genomic analysis, helping to identify
difficult-to-diagnose diseases more efficiently and lowering the
risk of misdiagnosis by identifying the primary underlying
genetic problem. Yet, it may go even beyond this. Sequencing of
multiple genes may also help to explain the often perplexing vari-
ability of genetic diseases, even within families, where affected
members all carry the same mutation. By identifying not only the
causative mutation in the primary disease gene, but also poten-
tially modifying variants in other related genes (oligogenic inheri-
tance) the variability may be at least partially explained.
Modification of the phenotype by additional variants in other
‘secondary’ disease genes has become a leading hypothesis for
the understanding of the phenotypic variability in ciliopathies,
for instance [10].
In this way, NGS may be able to facilitate personalized treat-
ment by enabling more detailed genetic counselling and progno-
ses. The hope is that it will also inform clinical management, by
identifying pathways contributing to the clinical phenotype, which
may be amenable to treatment. In some cases, genetic testing may
actually correct the clinical diagnosis with clear management
implications. Ars and Torra report on a man with isolated protei-
nuria, subsequently diagnosed with Fabry disease [11]. In another
report, patients referred with a clinical diagnosis of Bartter syn-
drome were found to actually suffer from congenital chloride diar-
rhoea [12]. In our own experience, patients referred for genetic
testing with a clinical diagnosis of ‘idiopathic hypokalaemia’ or
‘Dent disease’ were genetically diagnosed with distal renal tubular
acidosis, enabling appropriate treatment with alkali supplementa-
tion (E. Ashton et al., manuscript submitted for publication). Yet, as
always, new technologies provide not only promise, but also prob-
lems. With NGS, it is mainly the large number of variants identi-
fied and the uncertainty of their interpretation. As the promises of
NGS are elegantly discussed in the article by Ars and Torra [11], in
this editorial we will focus on the potential problems.
The more you sequence, the more you find
Each human genome contains 4–5 million variants from the
reference genome [13]! Five million! Imagine the scale of the
problem a geneticist faces when attributing relevance to them!
While WGS is currently still the exception, the ever-decreasing
costs are likely to establish it as a (if not ‘the’) routine test in the
near future. But even if we perform ‘only’ WES, concentrating
on the 2–3% of the genome that contains genes, we still find
thousands of variants in each individual. In a study from the
1000 Genomes Consortium, each genome contained 149–182
protein-truncating variants (such as nonsense mutations),
10 000–12 000 peptide-sequence-altering variants (missense
mutations) and 500 000 variants in known regulatory regions
(i.e. non-coding regions, such as promoters, as well as 50 and 30
untranslated regions) [13]. On average 24–30 recognized
disease-causing mutations are found in each of us [13]! So, how
can we make sense of this large number of variants?
Databases
Key to the first interpretation of identified variants is the compari-
son with databases that compile identified variants. These include
the gnomad browser (www.broadinstitute.org), Clinvar (https://
www.ncbi.nlm.nih.gov/clinvar/) HGMD (http://www.hgmd.cf.ac.
uk/ac/index.php) and Varsome (https://varsome.com/).
Increasingly, laboratories also maintain their own databases,
which is important to compile variants identified in the popula-
tion served, but which may also be related to the artefacts arising
due to either the sequencing technology or the subsequent assem-
bly of the sequencing products [14]. By running identified variants
against these databases, a large number (>99% for whole
genomes) can be excluded, mainly based on the frequency of a
given variant in the population. Variants found in >1% of the pop-
ulation are usually deemed benign, i.e. of no direct clinical rele-
vance. On the other hand, variants listed in databases such as
Clinvar, which contain confirmed mutations, would immediately
be flagged as potentially disease-causing in the patient.
However, these databases are not perfect and there are sev-
eral potential pitfalls:
• The presence of specific variants obviously varies with ethnicity.
Of critical importance is, therefore, to compare the identified var-
iants in a given patient against an ethnically matched dataset.
The frequency of a given variant in a database may thus attest
more to the predominant ethnicity within the database than its
potential pathogenicity.
• Mutations published as pathogenic may in fact be benign var-
iants. This is not unusual. If a researcher identifies a new disease
gene in a cohort of patients with a given clinical phenotype, then
some of these patients may have bona fide pathogenic muta-
tions, whereas others have benign polymorphisms. If informa-
tion about the frequency of these variants is not available at the
time of publications, these benign polymorphisms may be erro-
neously reported as pathogenic. There are several examples of
such ‘mutations’, reported even in the most prestigious journals,
which were subsequently deemed benign, based on the fre-
quency of these variants in the relevant population [15–18].
• Conversely, polymorphisms can sometimes be pathogenic.
A striking example is the Arg229Gln variant in NPHS2 (c.686G>A;
rs61747728), which is found in 1–2% of the Caucasian population,
but can be disease-causing when present ‘in trans’ with specific
other mutations [19]. Moreover, polymorphisms may still have a
modifier effect on an underlying disorder not directly connected
to this gene. For instance, variants in NOS3 and HBEGF have been
proposed as modifiers in ADPKD and CFHR5 nephropathy,
respectively [20, 21].
• As discussed above, we all harbour numerous pathogenic muta-
tions. Various reports suggest that each of us carries at least 100
loss-of-function mutations [22]. The majority of the mutations
are heterozygous and affect recessive disease genes, but increas-
ingly, individuals are found with recessive mutations, consid-
ered pathogenic and penetrant, yet who have no evidence of
being affected, a phenomenon labelled as ‘genetic resilience’
[23]. Careful correlation of identified variants with the clinical
phenotype is, thus, of critical importance.
Moreover, while careful comparison with databases can dra-
matically reduce the number of potentially disease-causing var-
iants, there typically remains a large number of variants for
which there is insufficient information available, the so-called
‘variants of uncertain significance’ (VUS). It is these VUS that cre-
ate the most headaches in interpretation and a variety of strat-
egies is employed to assess potential pathogenicity. Guidelines
have been proposed to increase the accuracy of such assess-
ments, which rely mainly on the following strategies [18, 24].
Predictions
An increasing number of mostly web-based tools, such as
Mutation taster, SIFT or Polyphen2, are available for the
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prediction of pathogenicity of identified variants. Different algo-
rithms are used for these predictions ranging from evolutionary
conservation of the affected amino acid to Hidden Markov
Models assessing relationships between protein domains to
determine the likelihood of a variant affecting protein function
[25–27]. However, when tested independently, these tools have
variable accuracy, partially dependent on the underlying gene
and nature of mutation [28, 29]. Most importantly, these tools
only provide a likelihood score of pathogenicity, yet no cer-
tainty. This is important to remember, when genetic analysis is
needed to make important clinical management decisions.
Another important deficiency of these tools is that by design
they primarily predict loss-of-function, yet some, typically domi-
nant diseases are caused by gain-of-function. Consider the exam-
ple reported by Ars and Torra of a 9-year-old girl with nephrotic
syndrome, in whom a heterozygous variant in TRPC6 was identi-
fied [11]. They speculate on pathogenicity, as the prediction algo-
rithms all indicated a high likelihood for this. TRPC6 encodes a
calcium channel important for podocyte function and dominant
mutations in this gene cause familial focal segmental glomerulo-
sclerosis (FSGS) type 2 [30]. Yet, these are typically gain-of-
function mutations, which increase calcium currents through the
channel, whereas the effect of heterozygous loss-of-function
mutations is controversial [31]. Indeed, suppression of TRPC6-
mediated currents is considered a potential treatment strategy
for podocyte injury [32]. Thus, the predictions of pathogenicity by
the various tools can be misleading in such a case. This demon-
strates the fundamental importance of an understanding of the
underlying disease mechanism when considering the potential
pathogenicity of an identified variant in a given gene.
Segregation
The same example also highlights another strategy to assess
pathogenicity of a given variant, namely, whether it segregates
with the disease in the family. In the case of the 9-year-old girl
with FSGS, three other family members were found to carry the
same variant, yet had no apparent clinical problem [11]. While
one could speculate about incomplete penetrance, the absence of
segregation in this family strongly argues against pathogenicity.
Conversely, incomplete penetrance can be a major problem in
some disorders, such as atypical haemolytic uremic syndrome
(aHUS). Heterozygous mutations in various complement-related
genes have been identified to cause susceptibility to aHUS, but
additional trigger(s) appear necessary [33]. Thus, it is not unusual
when assessing families with aHUS to find unaffected members
who carry the putative underlying variant, and using segregation
of the variant with the disease for proof of pathogenicity is there-
fore of limited value in such disorders.
Functional studies
Functional studies are typically time and work intensive and it is
of course impossible to perform these for thousands of variants
in each individual. Yet, if a single candidate variant is identified
as a potential cause, this can be considered. For instance, if a
splice variant of unknown pathogenicity is identified, analysis of
mRNA can help assess the impact of this variant on the mRNA
level [34]. Moreover, variants in ion channels can easily be
assayed for their functional impact by expression of the mutant
channels in experimental cells, as we have done, for instance, for
variants identified in patients with EAST syndrome [35–37]. This
is especially important when the type of functional impact (loss-
versus gain-of-function) is important, as discussed above for
TRPC6. Alternatively, identified variants can be expressed in ani-
mal models, such as mice, zebrafish or Drosophila, to better assess
their functional relevance [38, 39]. Yet, most diagnostic genetic
labs are not set up to perform functional studies and this is usu-
ally performed by research laboratories.
Ethical issues
When a large amount of genetic information is analysed, var-
iants identified may be relevant for other diseases rather than
the symptoms or diagnosis that prompted the genetic investiga-
tion. These so-called incidental findings can throw up serious
ethical issues. The best-known examples are variants in cancer
predisposition genes, such as BRCA1 or VHL [40].
The topic becomes particularly sensitive in paediatric medi-
cine, but is far too complex to be discussed in this editorial. The
interested reader is instead referred to other detailed reviews
and consensus statements on this topic [41–47].
Conclusions
NGS is revolutionizing genetic diagnosis by greatly facilitating
analysis of known disease genes and discovery of previously
unrecognized ones. It holds the promise of enabling personal-
ized medicine. However, the large amount of variants identified
also creates serious problems with respect to over- or misinter-
pretation. Only with the careful collection and annotation of
more and more sequencing data of people from all ethnic back-
grounds and with various diseases will we be able to better
understand the significance of specific variants and put them
into the context of the individual patient.
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